OverviewChartNewsTraderScreen

HSBC Call 248.466 22UA 15.01.2025/  DE000HG1J8C5  /

Frankfurt Zert./HSBC
2024-05-31  9:35:15 PM Chg.+0.004 Bid9:58:08 PM Ask9:58:08 PM Underlying Strike price Expiration date Option type
0.027EUR +17.39% 0.027
Bid Size: 150,000		 0.042
Ask Size: 150,000		 BIONTECH SE SPON. AD... 248.4658 - 2025-01-15 Call
GlobeNewswire 05-29 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire 05-21 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire 05-17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
TeleTrader 05-06 BioNTech's Q1 revenue slumps 85% to €187.6M
GlobeNewswire 05-06 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 04-22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire 04-07 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
TeleTrader 03-20 BioNTech Q4 revenue plunges 65% to €1.48B
GlobeNewswire 03-20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire 03-20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire 03-11 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire 03-07 BioNTech Announces Planned Retirement of Sean Marett
GlobeNewswire 03-06 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire 02-08 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire 01-31 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire 01-22 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
TeleTrader 01-09 BioNTech sees $3.3B revenue for 2024, expanding into oncology
GlobeNewswire 01-09 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 2023-12-21 BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire 2023-12-18 BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire 2023-12-12 BioNTech to Inaugurate First African Site on December 18, 2023
TeleTrader 2023-11-06 BioNTech Q3 revenue plummets 74% to €895M
GlobeNewswire 2023-11-06 BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire 2023-10-26 Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Agains...
GlobeNewswire 2023-10-23 BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advance...